RegMed - Departement EWI · 11 Wij gaan na vandaag een nieuwe fase in van RegMed XB Prioriteiten voor komend jaar (niet uitputtend) Van projectorganisatie ... >Bouwen aan community

28 Oktober 2019

In a nutshell

RegMed XB

Frank P. Luyten

Med/Sci Director

2

We are heading into the era of Regenerative Medicine, which will benefit our society, patients and economy

Society – Tackling the rising challenge of chronic diseases in an aging population

1

Patients – Prevention and cures instead of long term care for chronic patients

2

Economy – Providing major economic opportunities and building a new industry

3

Science – Booming scientific field4

Regenerative medicine aims to restore and/or replace tissue function

3

We are building a unique ecosystem

Moonshotsmission-orientedexcellent research

Connection & building a community

Translationstart-up

companies

Public-Private Fund & PPS collaboration

Build uniqueproduction & technologyinfrastructure

Investmentsin (scaling) start-ups

4

RegMed XB Foundation has a decision making role in two of the pillars

Research Translation Business Dev. & Acceleration

Public-private entrepreneurship Seed capital

Infrastructure & exploitation

Decision making by RegMed XB Foundation

3

Moonshot teams/ projects

Valorization team

IP PoC Skills

Central

Regional

National fund

Investment committee

Fund managers

Reg-ionalco-fin-ancein pro-jects

Reg-ionalfund

Reg-ionalfund

Reg-ionalfund

Reg-ionalfund

Infra

Opera-ting comp.

Infra

Opera-ting comp.

Infra

Opera-ting comp.

Infra

Opera-ting comp.

RegMed XB Foundation

Cooperation and coordination

Joint proposition towards customers

Management and coordination of the initiative, incl. connecting pillars, aligning organizations in pillars, community building, and organizing platform meetings – Makes agreements with organizations in pillars

Decision making by foundation board through research budgets (e.g. PPS-allowance) and capacities in the Foundation

Platform Meeting of universities, health foundations and governments (regional and national) that participate and invest in the different pillars/entities of RegMed XB (alike the current Stakeholder Steering Committee)

5

Four Moonshots (€35 million investment as per today)

Therapy fortype I diabetes

Subunit of bioengineered

kidney

Bioengineeredjoint

Regenerated

heart

6

Building Regional Manufacturing & Technology Platforms

Stem cells (e.g. iPSCs and

(bio)materials

Microtissue(~100 µm)

Mesotissue(~mm-cm)

Macrotissue/organs

(~10 cm)

7

Allogenic

iPS cells

Autologous

stem cells

(hPDC)

Macro-tissue assembly

Designed bioprinting

LAB / Extrusion

Personalized tissue implant

Cell culture/expansion

Automated

Scaleable

Closed (GMP)

µ-tissue formation

Robotic culture

Monitored

Closed (GMP)

Clinical

trials

On- & in-line QA (PAT) for VIPP: Viability, Identity, Purity, Potency

Metabolomics, Transcriptomics

Single RNA seq, Micro-RNAi

Raman spectrometry, Lens free imaging,

Wave-based immuno-sensing

Platform control

softwareBiological data

storage and analysis

ORBITManufacturing platform

Cell

depository

Pre-clinical testing

Rodent, Rabbit

Large animal

(sheep, mini-pig)

8

RegMed XB aims to grow into a sizeable, internationally leading institute

Development RegMed XB

Funding of RegMed XB

Additional funding

Geographical scale up

> EUR 250 m funding over 10 years

> ~500 researchers (public and private) in the institute

> Mobilize additional EU and private funding

> Geographical scale up into Germany and other Dutch and Belgium regions

€

9

The Governance model of RegMed XB

Supervisory Board

(SB/ RvT)

General Director

(0.8-fte)

Medical Scientific Director

(0.5 fte)

International Scientific Advisory

Boards (ISAB)

Moonshot leadership teams and research

teams

Board of Directors (BoD)

Valorisation PPE Fund Seed FundsTechnology Platforms

Strategic Advisory Board (StAB)

General Assembly

(GA)

RE

GM

ED

XB

HQ

PIL

LA

RS

FOUNDATION

Scientific Advisory Board

(SAB)

Strategic Valorization Board (SVB)

Operational team (OT) incl. CFO

Patient Advocate

(0.1 fte)

New Business Development Director

(0.5 fte)

Non-executiveExecutives

Participants Assembly (PA)

July 2019

10

Coördinerende activiteiten zijn gedefinieerd, en budget daarvoor gemobiliseerd

EUR 0,8 m

BD&A Cross-

regional

coordination

Facilitation

& support

Research

Excellence

Annual

Budget

Gedragen door …

>4 gezondheidsfondsen

>4 Nederlandse universiteiten (incl. UMCs)

>4 Nederlandse provincies

>Nederlandse overheid

>Vlaamse partners

…. en toekomstige partners

11

Wij gaan na vandaag een nieuwe fase in van RegMed XB

Prioriteiten voor komend jaar (niet uitputtend)

Van projectorganisatie naar instituut

> Implementeren van de nieuwe governance structuur

> Be-mensen van de organisatie

> Maken van contracten met partners en financiers

Van mobiliseren naar implementeren

> Opzetten van de Stoeterij (o.a. met aanvraag Toekomstfonds)

> Realiseren van het PPE fonds

> Realiseren regionale infrastructuren en gezamenlijke propositie rondom productie platforms (eg ORBIT)

> Bouwen aan community – 5 februari jaarevent/opening

12

1. Duurzaamheid ?2. Meten van Impact ?3. Identificatie en inbrenging van nieuwe partners ?

Vragen: